Healey ALS MyMatch

Overview

Launched in 2025, the goal of the Healey ALS MyMatch program is to accelerate the path to new ALS therapies. ALS MyMatch is an ongoing series of patient-centric Phase 1b/2a biomarker-driven clinical trials. These trials utilize genetic and biofluid markers (biomarkers) to select participants and assess a range of investigational products, including experimental and repurposed medications, cell-based therapies, gene-targeted therapies, and devices.

ALS MyMatch trials will be conducted at multiple rapid-enrolling U.S. centers from the Northeast ALS (NEALS) Consortium. Successful ALS MyMatch investigational products may be considered for future regimens of the HEALEY ALS Platform Trial, a late phase clinical efficacy trial, or transition to standalone Phase 3 trials. This collaborative ALS MyMatch initiative is made possible through generous philanthropic support to the Sean M. Healey & AMG Center for ALS at MGH.

At the heart of ALS MyMatch lies the value of rigor and innovation to confidently answer critical scientific questions in early stages of drug development and thoughtfully inform future therapeutic development in ALS.

Community Webinars

We are committed to an ongoing dialogue with the entire ALS community. Register to attend upcoming Healey ALS MyMatch community Q&A webinars.

• Thursday, June 5th, 5:00 pm EDT: ALS MyMatch Discussion with Dr. Suma Babu - Register
• Monday, June 9th, 11:00 am EDT: NEALS Webinar - ACACIA: Trial of Oral Digoxin in ALS - Register

Partner With Us

Healey ALS MyMatch is designed to support biomarker-driven Phase 1b/2a clinical trials in ALS. The Sean M. Healey & AMG Center for ALS is seeking applications of experimental therapies for inclusion in this clinical trial initiative on a rolling basis. ALS MyMatch trials are best suited for therapies focused on biological efficacy, target engagement, CNS penetrance, pharmacokinetics and/or dose finding. We invite investigators from both academia and industry to apply for consideration in ALS MyMatch.

Learn more and apply

Confidential Disclosure Agreements (CDAs) are executed between MGH and the institution or company before the ALS MyMatch Therapy Application Form is submitted.

Download the CDA template (Word document)